Endocrine Therapy plus Bevacizumab for Advanced Breast Cancer

Although enthusiasm has waned for bevacizumab as a component of breast cancer treatment, large clinical trials that explored its use in different clinical settings continue to be reported as data have matured. Moreover, even though the FDA rescinded approval of bevacizumab as therapy for metastatic disease, guidelines in the U.S. and Europe continue to list the drug as a treatment option.

Much of the data have focused on the use bevacizumab plus chemotherapy, but small pilot studies have suggested a role for bevacizumab plus endocrine therapy (ET) in this setting. To test this approach further, Spanish and German investigators conducted an industry-supported, multicenter, randomized, open-label, phase III trial (LEA) that compared ET (letroz…